ReviewExpert review of molecular diagnostics2013
Next-generation sequencing: a powerful tool for the discovery of molecular markers in breast ductal carcinoma in situ.
Review in Expert review of molecular diagnostics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02121873 (The Breast Duct), which is not on this map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Breast Duct: Pilot Study of Genomic Sequencing of Exfoliated Ductal Cells Obtained Through Endoscopy and Lavage
Who cites it
21 citing papers in PubMed, 48 citations in OpenAlex.
- Review
- Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance.Signal transduction and targeted therapy · 2024Review
- Review
- Sprouty4 negatively regulates ERK/MAPK signaling and the transition from in situ to invasive breast ductal carcinoma.PloS one · 2021Article
- Stage-specific protein-domain mutational profile of invasive ductal breast cancer.BMC medical genomics · 2020Article
- The role of MRI and clinicopathologic features in predicting the invasive component of biopsy-confirmed ductal carcinoma in situ.BMC medical imaging · 2020Article
- Ductal carcinoma in situ of the breast: immune cell composition according to subtype.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020Article
- In Vitro Models for Studying Invasive Transitions of Ductal Carcinoma In Situ.Journal of mammary gland biology and neoplasia · 2019Review
- Ras and Rap1: A tale of two GTPases.Seminars in cancer biology · 2019Review
- Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation.Neoplasia (New York, N.Y.) · 2018Article
- Long noncoding RNA ROR promotes breast cancer by regulating the TGF-β pathway.Cancer cell international · 2018Article
- Novel applications of next-generation sequencing in breast cancer research.Genes & diseases · 2017Review
- Patient-derived xenograft (PDX) models in basic and translational breast cancer research.Cancer metastasis reviews · 2016Review
- Detection of gene copy number alterations in DCIS and invasive breast cancer by QM-FISH.American journal of translational research · 2016Article
- Article
- How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization.Mini reviews in medicinal chemistry · 2016Review
- Whole genome and transcriptome sequencing of matched primary and peritoneal metastatic gastric carcinoma.Scientific reports · 2015Article
- Molecular biomarkers screened by next-generation RNA sequencing for non-sentinel lymph node status prediction in breast cancer patients with metastatic sentinel lymph nodes.World journal of surgical oncology · 2015Article
- MicroRNA expression profiling of lactating mammary gland in divergent phenotype swine breeds.International journal of molecular sciences · 2015Article
- Exome sequencing: new insights into lipoprotein disorders.Current cardiology reports · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Mammographic screening leads to frequent biopsies and concomitant overdiagnosis of breast cancer, particularly ductal carcinoma in situ (DCIS). Some DCIS lesions rapidly progress to invasive carcinoma, whereas others remain indolent. Because we cannot yet predict which lesions will not progress, all DCIS is regarded as malignant, and many women are overtreated. Thus, there is a pressing need for a panel of molecular markers in addition to the current clinical and pathological factors to provide prognostic information. Genomic technologies such as microarrays have made major contributions to defining subtypes of breast cancer. Next-generation sequencing (NGS) modalities offer unprecedented depth of expression analysis through revealing transcriptional boundaries, mutations, rare transcripts and alternative splice variants. NGS approaches are just beginning to be applied to DCIS. Here, the authors review the applications and challenges of NGS in discovering novel potential therapeutic targets and candidate biomarkers in the premalignant progression of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.